Two UB drug development and discovery projects have received investments from the Empire Discovery Institute.
Subscribe
One project focuses on an immunotherapy platform developed by UB pharmacy researcher Sathy Balu-Iyer and his team that could benefit patients who are receiving gene therapy for a variety of diseases. The other will seek to design a therapy for multiple sclerosis (MS) that leverages a novel drug target discovered by a team led by UB medical researcher M. Laura Feltri.
The institute will advance both efforts through its Medicines Discovery Award Program, a competitive incubator and accelerator program designed to identify and advance promising early-stage drug discovery into early proofs of concept. Successful projects will exit the program as either a licensing transaction to a strategic pharmaceutical partner or as an Empire Discovery Institute-created startup company.
Two UB drug development and discovery projects have received investments from the Empire Discovery Institute.
One project focuses on an immunotherapy platform developed by UB pharmacy researcher Sathy Balu-Iyer and his team that could benefit patients who are receiving gene therapy for a variety of diseases. The other will seek to design a therapy for multiple sclerosis (MS) that leverages a novel drug target discovered by a team led by UB medical researcher M. Laura Feltri.
The institute will advance both efforts through its Medicines Discovery Award Program, a competitive incubator and accelerator program designed to identify and advance promising early-stage drug discovery into early “proofs of concept.” Successful projects will exit the program as either a licensing transaction to a strategic pharmaceutical partner or as an Empire Discovery Institute-created startup company.
University at Buffalo
Teams will seek to develop treatment options that could benefit patients with multiple sclerosis, hemophilia and more
BUFFALO, N.Y. Two University at Buffalo drug development and discovery projects have received investments from the Empire Discovery Institute.
One project focuses on an immunotherapy platform developed by UB pharmacy researcher Sathy Balu-Iyer and his team that could benefit patients who are receiving gene therapy for a variety of diseases. The other will seek to design a therapy for multiple sclerosis (MS) that leverages a novel drug target discovered by a team led by UB medical researcher M. Laura Feltri.